WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; andOppenheimer 35th Annual Healthcare Life Scienc ...

Core Insights - Kymera Therapeutics, Inc. (KYMR) announced its business goals for 2025, focusing on its immunology pipeline, leading to an 8% increase in stock price and a 47.2% rise over the past year compared to a 16% decline in the industry [1] Pipeline Updates - Kymera is developing KT-621, a first-in-class oral degrader of STAT6, showing dupilumab-like activity and strong safety data in preclinical models [2] - Recruitment is ongoing for a phase I study of KT-621, which has potential applications in various Th2 diseases, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease [3] - Kymera plans to complete the phase I study and report data in Q2 2025, with a phase lb study in atopic dermatitis also set for Q2 2025 and a phase IIb study planned for Q4 2025 [4] Additional Candidates - Kymera is evaluating KT-295, a first-in-class oral degrader of TYK2, with plans to file an investigational new drug application and initiate a phase I study in Q2 2025, expecting data in Q4 2025 [5] - KT-474 (SAR444656), an IRAK4 degrader, is in development for immune-inflammatory diseases, with Sanofi planning to expand ongoing mid-stage studies toward pivotal studies following positive preliminary data [6][7] - Kymera and Sanofi aim to advance KT-474 in phase IIb studies for hidradenitis suppurativa and atopic dermatitis, with primary completion expected in 2026 [8] Future Developments - Kymera plans to announce a new immunology program targeting an undrugged transcription factor in H1 2025, with clinical testing expected in early 2026 [10] - The company decided not to continue developing KT-333 and KT-253 beyond phase I due to a strategic focus on its immunology pipeline [10] Financial Position - As of December 31, 2024, Kymera had an estimated $850 million in cash, sufficient to fund operations into mid-2027 [11]

Kymera Therapeutics, Inc. (KYMR) shares rallied 7.8% in the last trading session to close at $40.12. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.6% loss over the past four weeks.Shares gained as investors were impressed by the pipeline updates provided by the company at the J.P. Morgan Annual Healthcare Conference. Kymera has a sound cash position and ended 2024 with an estimated cash of $850 million, ...

Exhibit 99.2 January 2025 J.P. Morgan Healthcare Conference Nello Mainolfi, Ph.D., Founder, President and CEO ,KYMERA This presentation contains forward-looking statements within the meanine of the Private Securities Litiation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, inplied and express statements about our stratesy, business plans and digictives for the inclinerines for the preclinical and cl regarding timing, success and data announcements of ...

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively KT-295 (TYK2) to advance into Phase 1 testing in 2Q25 with data expected in late 2025 KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD ongoing, with completion expect ...

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an ...

Kymera Therapeutics, Inc. (KYMR) reported a loss of 82 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 83 cents. In the year-ago quarter, Kymera reported a loss of 90 cents per share.Collaboration revenues totaled $3.7 million, which missed the Zacks Consensus Estimate of $9 million. The reported figure increased 20.8% from the year-ago level.Collaboration revenues in the third quarter were mostly earned due to the company’s association with bigwig Sanof ...

Core Viewpoint - Kymera Therapeutics reported a quarterly loss of $0.82 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.83, and an improvement from a loss of $0.90 per share a year ago [1][2] Financial Performance - The company posted revenues of $3.74 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 58.27%, compared to $4.73 million in revenues a year ago [2] - Over the last four quarters, Kymera Therapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - Kymera Therapeutics shares have increased approximately 87.2% since the beginning of the year, outperforming the S&P 500's gain of 21.9% [3] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.78 on revenues of $13.41 million, and for the current fiscal year, it is -$2.85 on revenues of $58.33 million [7] - The estimate revisions trend for Kymera Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Kymera Therapeutics belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

Core Insights - Kymera Therapeutics has received FDA clearance for its investigational New Drug application for KT-621, a first-in-class oral STAT6 degrader aimed at treating multiple allergic and atopic diseases [1][3] - The company plans to initiate a phase I study for KT-621 in healthy volunteers later this month, with data expected in the first half of 2025 [2] Company Pipeline Progress - Kymera recently raised $225 million through a public offering to advance its pipeline of degrader programs [5] - The company is also progressing with KT-474, a first-in-class IRAK4 degrader, with plans for pivotal studies following positive preliminary safety and efficacy data [6][7] - Ongoing phase I studies for KT-253 and KT-333 are showing promising antitumor responses, with enrollment expected to complete in the second half of 2024 [9][10] Competitive Landscape - Sanofi and Regeneron's Dupixent, an injectable monoclonal antibody, is an established therapy for allergic and atopic diseases, validating the STAT6 targeting approach [4]